Odyssey Health, Inc.
No SEC Form 4 filings for $ODYY in the last 30 days.
See all $ODYY insider activity →Odyssey Health reported a net loss of $5.73M for fiscal 2026, widening from a $1.74M loss in 2025. Diluted loss per share was $0.05, up from $0.02. The company is developing CardioMap and Save-A-Life devices, neither cleared for sale. Future plans depend on securing funding.
Odyssey Health (ODYY) extended the maturities of two notes to January 31, 2027. The company amended a convertible note with LGH Investments and a note with Peter J. D'Arruda on September 29, 2026, to preserve liquidity and provide repayment flexibility. All other terms remain unchanged.
Odyssey Health, Inc. (ODYY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 29, 2026, Odyssey Health, Inc., entered into Amendment No. 13 with LGH Investments, LLC. Pursuant to Amendment No. 13, the parties have agreed to extend the maturity date of the note to January 31, 2027. All othe
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ODYY (Odyssey Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ODYY coverage spans corporate actions and earnings.
The loss expansion signals higher cash burn and may pressure the stock lower.
The note extensions do not change interest rates or conversion terms, so the immediate price impact is expected to be minimal.
The note extensions are a modest corporate‑action with limited market impact.
AlphAI scores every news story that mentions ODYY with an AI model for sentiment and relevance, and aggregates insider trades from Odyssey Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Odyssey Health reported a net loss of $5.73M for fiscal 2026, widening from a $1.74M loss in 2025. Diluted loss per share was $0.05, up from $0.02. The company is developing CardioMap and Save-A-Life devices, neither cleared for sale. Future plans depend on securing funding.
1 min readOdyssey Health (ODYY) extended the maturities of two notes to January 31, 2027. The company amended a convertible note with LGH Investments and a note with Peter J. D'Arruda on September 29, 2026, to preserve liquidity and provide repayment flexibility. All other terms remain unchanged.
1 min readOdyssey Health, Inc. (ODYY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 29, 2026, Odyssey Health, Inc., entered into Amendment No. 13 with LGH Investments, LLC. Pursuant to Amendment No. 13, the parties have agreed to extend the maturity date of the note to January 31, 2027. All othe
1 min read
